Literature DB >> 10980601

A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK.

P J Mitchell1, E A Sara, M R Crompton.   

Abstract

The brk gene encodes a non-receptor tyrosine kinase that has been found to be overexpressed in approximately two thirds of breast tumours. Using a yeast two-hybrid based screen, we have cloned cDNAs encoding a novel protein, BKS, that is a substrate for the kinase activity of BRK and has the characteristics of an adaptor protein. BKS possesses an N-terminal PH-like domain followed by an SH2-like domain. In co-transfection experiments, high levels of phosphotyrosine were observed on BKS and BRK was found to be associated with BKS, both of which were dependent on the catalytic activity of BRK. The phosphorylation of and association with BKS by BRK was also dependent on the SH2-like domain present within BKS. In addition, BKS recruited an unidentified 100 kDa protein that was also phosphorylated on tyrosine residues in the presence of BRK. We have determined that the BKS protein is expressed in most adult human tissues. Oncogene (2000) 19, 4273 - 4282

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980601     DOI: 10.1038/sj.onc.1203775

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.

Authors:  Osamu Ikeda; Yuichi Sekine; Akihiro Mizushima; Misa Nakasuji; Yuto Miyasaka; Chikako Yamamoto; Ryuta Muromoto; Asuka Nanbo; Kenji Oritani; Akihiko Yoshimura; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane.

Authors:  Jessica Gierut; Yu Zheng; Wenjun Bie; Robert E Carroll; Susan Ball-Kell; Andrea Haegebarth; Angela L Tyner
Journal:  Gastroenterology       Date:  2011-07-08       Impact factor: 22.682

4.  Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.

Authors:  Andrea Haegebarth; Wenjun Bie; Ruyan Yang; Susan E Crawford; Valeri Vasioukhin; Elaine Fuchs; Angela L Tyner
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 5.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.

Authors:  Midan Ai; Ke Liang; Yang Lu; Songbo Qiu; Zhen Fan
Journal:  Cancer Biol Ther       Date:  2013-01-04       Impact factor: 4.742

7.  Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.

Authors:  Hsin-Yi Chen; Che-Hung Shen; Yuh-Tyng Tsai; Feng-Chi Lin; Yuan-Ping Huang; Ruey-Hwa Chen
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 8.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

9.  Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

Authors:  Nancy E Castro; Carol A Lange
Journal:  Breast Cancer Res       Date:  2010-08-05       Impact factor: 6.466

10.  STAP-2 negatively regulates both canonical and noncanonical NF-kappaB activation induced by Epstein-Barr virus-derived latent membrane protein 1.

Authors:  Osamu Ikeda; Yuichi Sekine; Teruhito Yasui; Kenji Oritani; Kenji Sugiyma; Ryuta Muromoto; Norihiko Ohbayashi; Akihiko Yoshimura; Tadashi Matsuda
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.